MLchartDataset catalogue

oral sodium phenylbutyrate

Term · Oncology and biomedicine · MLC-T-ONC-015702

An orally active derivative of the short-chain fatty acid butyrate with potential antineoplastic activity. 4-Phenylbutyrate inhibits histone deacetylase, resulting in cell cycle gene expression modulation, reduced cell proliferation, increased cell differentiation, and apoptosis. This agent also initiates fragmentation of genomic DNA, resulting in decreased DNA synthesis and the inhibition of tumor cell migration and invasion.

Table 1. Record
IdentifierMLC-T-ONC-015702
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-015702",
  "term": "oral sodium phenylbutyrate",
  "field": "Oncology and biomedicine",
  "definition": "An orally active derivative of the short-chain fatty acid butyrate with potential antineoplastic activity. 4-Phenylbutyrate inhibits histone deacetylase, resulting in cell cycle gene expression modulation, reduced cell proliferation, increased cell differentiation, and apoptosis. This agent also initiates fragmentation of genomic DNA, resulting in decreased DNA synthesis and the inhibition of tumor cell migration and invasion.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/oral-sodium-phenylbutyrate/"
}

Record 12,329 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.